C4 Therapeutics Ownership | Who Owns C4 Therapeutics?

Overview Forecast RevenueFinancials Chart

C4 Therapeutics Ownership Summary

C4 Therapeutics is owned by 77.02% institutional investors, 9.75% insiders, and 13.23% retail investors. Wasatch advisors lp is the largest institutional shareholder, holding 10.46% of CCCC shares. Wasatch Ultra Growth is the top mutual fund, with 7.25% of its assets in C4 Therapeutics shares.

CCCC Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	C4 Therapeutics	77.02%	9.75%	13.23%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.59%	11.10%	-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Wasatch advisors lp	7.42M	10.46%	$10.62M
Lynx1 capital management lp	7.10M	10.23%	$11.36M
Soleus capital management	6.98M	9.83%	$9.98M
Orbimed advisors	6.83M	9.62%	$9.77M
Blackrock	4.55M	6.61%	$21.03M
Vanguard group	3.35M	4.81%	$12.05M
Blackrock funding, inc. /de	1.83M	2.58%	$2.61M
Bank of america corp /de/	1.77M	2.57%	$8.17M
Geode capital management	1.38M	1.98%	$4.97M
State street	1.22M	1.76%	$4.40M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lynx1 capital management lp	7.10M	4.07%	$11.36M
Soleus capital management	6.98M	0.66%	$9.98M
Orbimed advisors	6.83M	0.24%	$9.77M
Bain capital life sciences investors	1.11M	0.20%	$1.59M
Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group	85.00K	0.08%	$121.55K
Tang capital management	900.00K	0.07%	$1.29M
Wasatch advisors lp	7.42M	0.06%	$10.62M
Intrepid family office	40.00K	0.05%	$57.20K
Atom investors lp	190.18K	0.02%	$271.96K
Hennion & walsh asset management	208.77K	0.01%	$298.54K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	4.55M	0.00%	3.65M
Wasatch advisors lp	7.42M	0.06%	700.25K
Morgan stanley	1.14M	0.00%	623.75K
Ubs group	757.85K	0.00%	423.77K
Lynx1 capital management lp	7.10M	4.07%	245.39K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-4.88M
Blackrock funding, inc. /de	1.83M	-	-3.46M
Commodore capital lp	-	-	-3.41M
Samlyn capital	-	-	-3.02M
State street	1.22M	0.00%	-1.58M

New Positions

Holder	Shares	% Assets	Change	Value
Susquehanna portfolio strategies	126.90K	0.00%	126.90K	$181.47K
Brookstone capital management	29.32K	0.00%	29.32K	$41.94K
Crestwood advisors group	29.00K	0.00%	29.00K	$41.47K
Lpl financial	22.10K	0.00%	22.10K	$102.10K
Dynamic technology lab private	21.48K	0.00%	21.48K	$31.00K

Sold Out

Holder	Change
Gradient investments	-25.00
Coldstream capital management	-52.00
Capital performance advisors llp	-54.00
Rothschild investment	-70.00
Cape investment advisory	-100.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	100	-13.04%	54,689,267	-14.68%	77	0.90%	55	-19.12%	33	17.86%
Mar 31, 2025	6	-95.20%	21,025,800	-67.35%	30	0.35%	4	-93.85%	1	-96.97%
Dec 31, 2024	122	-5.43%	64,367,933	0.29%	92	1.09%	63	-7.35%	33	3.13%
Sep 30, 2024	126	5.88%	64,029,825	5.20%	91	1.18%	67	1.52%	33	-2.94%
Jun 30, 2024	119	7.21%	60,865,031	4.84%	88	1.23%	66	-1.49%	34	25.93%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Wasatch Ultra Growth	5.15M	7.25%	593.72K
Vanguard US Total Market Shares ETF	2.14M	3.01%	-
Vanguard Total Stock Mkt Idx Inv	2.03M	2.85%	-44.74K
Biotech Growth Ord	1.75M	2.46%	-
SPDR® S&P Biotech ETF	1.57M	2.22%	22.34K
iShares Russell 2000 ETF	1.53M	2.16%	-
Wasatch Micro Cap	758.27K	1.07%	-483.88K
Fidelity Small Cap Index	623.59K	0.88%	-8.75K
Vanguard Institutional Extnd Mkt Idx Tr	608.71K	0.86%	-231.45K
iShares Russell 2000 Value ETF	560.98K	0.79%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 18, 2025	Boyle Scott N	Chief Business Officer	Sell	$2.11K
Feb 14, 2025	Boyle Scott N	Chief Business Officer	Sell	$1.54K
Feb 08, 2023	Koppikar Utpal	-	Buy	$31.74K
Apr 12, 2022	Hirsch Andrew	President & CEO	Buy	$84.00K
Jan 04, 2022	Crystal Adam	Chief Medical Officer	Sell	$440.55K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	-
2025 Q2	-	-
2025 Q1	-	2
2024 Q4	-	-
2024 Q3	-	-

CCCC Ownership FAQ

Who Owns C4 Therapeutics?

C4 Therapeutics shareholders are primarily institutional investors at 77.02%, followed by 9.75% insiders and 13.23% retail investors. The average institutional ownership in C4 Therapeutics's industry, Biotech Stocks , is 306.59%, which C4 Therapeutics falls below.

Who owns the most shares of C4 Therapeutics?

C4 Therapeutics’s largest shareholders are Wasatch advisors lp (7.42M shares, 10.46%), Lynx1 capital management lp (7.1M shares, 10.23%), and Soleus capital management (6.98M shares, 9.83%). Together, they hold 30.52% of C4 Therapeutics’s total shares outstanding.

Does Blackrock own C4 Therapeutics?

Yes, BlackRock owns 6.61% of C4 Therapeutics, totaling 4.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 21.03M$. In the last quarter, BlackRock increased its holdings by 3.65M shares, a 402.93% change.

Who is C4 Therapeutics’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is C4 Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.07% of its assets in 7.1M C4 Therapeutics shares, valued at 11.36M$.

Who is the top mutual fund holder of C4 Therapeutics shares?

Wasatch Ultra Growth is the top mutual fund holder of C4 Therapeutics shares, with 7.25% of its total shares outstanding invested in 5.15M C4 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools